Hepatocellular carcinoma is a primary malignancy of the liver; the majority of cases arise from underlying liver cirrhosis. Treatment of hepatocellular carcinoma incorporates a variety of multimodal approaches; advanced (metastatic) disease is treated with palliative intent. Bayer HealthCare/Amgen/Onyx’s Nexavar is the only agent approved for first-line advanced hepatocellular carcinoma, and Bayer HealthCare’s Stivarga and Bristol-Myers Squibb’s Opdivo (United States only) are approved as second-line treatments. The late-phase therapy pipeline for hepatocellular carcinoma is focused on the advanced setting and encompasses a diverse range of mechanisms of action (MOAs). Because the hepatocellular carcinoma therapy market is largely untapped, developers of efficacious drugs can reap high commercial rewards.
- How large is the treatable hepatocellular carcinoma population, and how will drug-treatment rates change over time?
- How is hepatocellular carcinoma currently treated, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
- Who are the key players in the late-phase development pipeline for hepatocellular carcinoma? Which agents or drug classes are most promising? What therapies of note are progressing in earlier phases?
- Which emerging therapies do we forecast to enter the hepatocellular carcinoma market during the forecast period? What sales/uptake could they secure in this niche oncology indication?
Market covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: Eight country-specific interviews with thought leaders (medical oncologists and hepatologists).
Epidemiology: Diagnosed incident cases of hepatocellular carcinoma: early-stage hepatocellular carcinoma, intermediate-stage hepatocellular carcinoma, and advanced-stage hepatocellular carcinoma.
Population segments in market forecast: Early-stage hepatocellular carcinoma, intermediate-stage hepatocellular carcinoma, advanced first-line hepatocellular carcinoma, and advanced second-line hepatocellular carcinoma.
Emerging therapies: Phase III: 10 drugs; Phase II: 22 drugs; coverage of select Phase I and preclinical products.
Product Description: Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.